Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.69 |
| ▸ | PNMT | P11086 | 1/20 | 0.56 |
| ▸ | ACP3 | P15309 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30213812 | 1.00 | CES2 (0.69) | CES2PNMTACP3LMNAMAPK1 | |
| SCHEMBL5159938 | 1.00 | CES2 (0.69) | CES2PNMTACP3LMNAMAPK1 | |
| SCHEMBL5159944 | 1.00 | CES2 (0.69) | CES2PNMTACP3LMNAMAPK1 | |
| SCHEMBL29658570 | 1.00 | CES2 (0.69) | CES2PNMTACP3LMNAMAPK1 | |
| SCHEMBL23972632 | 0.90 | CES2 (0.57) | CES2PNMTACP3LMNAMAPK1 | |
| SCHEMBL30604468 | 0.86 | CES2 (0.54) | CES2ACP3LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL23972894 | 0.86 | CES2 (0.54) | CES2ACP3LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL5527951 | 0.84 | CES2 (0.67) | CES2PNMTACP3IDO1TDO2 | |
| SCHEMBL29658610 | 0.84 | CES2 (0.67) | CES2PNMTACP3IDO1TDO2 | |
| SCHEMBL18952889 | 0.84 | CES2 (0.57) | CES2PNMTACP3KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| CN-115427409-A | Pyrimidin-4 (3H) -one derivatives as TRPV4 antagonists | 拉夸里亚创药株式会社 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |
| US-10857517-B2 | Porous chiral materials and uses thereof | NANKAI UNIVERSITY (CN) | 2020-12-08 | — | — | US | disclosed |
| CN-109689667-A | Porous chiral material and use thereof | 南开大学 | 2019-04-26 | — | — | CN | disclosed |
| US-7642358-B2 | Substituted phenylacetic acids | METABOLEX, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642358-B2 | Substituted phenylacetic acids | METABOLEX, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| WO-2004037760-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKOXY-1-(TRIFLUOROMETHYL-SUBSTITUTED PHENYL)ETHANOL DERIVATIVES | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-05-06 | — | — | WO | disclosed |
| US-4297489-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
| US-4172196-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1979-10-23 | — | — | US | disclosed |
| US-4112228-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-3985738-A | ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | ADH1A, ADH1C, ADH5 | CES2 115/4885PNMT 245/4885ACP3 2546/4885 |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | CES2 4819/4885PNMT 1811/4885ACP3 846/4885 |
| US-10857517-B2 | Porous chiral materials and uses thereof | ANXA7, XDH, OPRM1 | CES2 3541/4885PNMT 1152/4885ACP3 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.